Evidence map›Paper›PMID 25483062›Full record

ArticleCell cycle (Georgetown, Tex.)2015

Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin.

Vladimir N Anisimov, Irina G Popovich, Mark A Zabezhinski, Peter A Egormin, Maria N Yurova, Anna V Semenchenko, Margarita L Tyndyk, Andrey V Panchenko, Alexandr P Trashkov, Andrey G Vasiliev and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Reproductive Longevity and Aging: Geroscience Approaches to Maintain Long-Term Ovarian Fitness.The journals of gerontology. Series A, Biological sciences and medical sciences · 2021
    Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Vladimir N Anisimova N.N. Petrov Research Institute of Oncology ; St. Petersburg , Russia.
Irina G Popovich
Mark A Zabezhinski
Peter A Egormin
Maria N Yurova
Anna V Semenchenko
Margarita L Tyndyk
Andrey V Panchenko
Alexandr P Trashkov
Andrey G Vasiliev
Nikolai V Khaitsev
Institute of Oncology NN Petrov · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The perinatal (prenatal and early neonatal) period is a critical stage for hypothalamic programming of sexual differentiation as well as for the development of energy and metabolic homeostasis. We hypothesized that neonatal treatment with antidiabetic drug biguanide metformin would positively modify regulation of growth hormone--IGF-1--insulin signaling pathway slowing down aging and improving cancer preventive patterns in rodents. To test this hypothesis male and female 129/Sv mice were s.c. injected with metformin (100 mg/kg) at the 3rd, 5th and 7th days after birth. Metformin-treated males consumed less food and water and their body weight was decreased as compared with control mice practically over their entire lifespan. There were no significant differences in age-related dynamics of food and water consumption in females and they were heavier than controls. The fraction of mice with regular estrous cycles decreased with age and demonstrated a tendency to decrease in the females neonatally treated with metformin. Neonatal exposure to metformin practically failed to change the extent of hormonal and metabolic parameters in blood serum of male and female mice. In males, neonatal metformin treatment significantly increased the mean life span (+20%, P < 0.05) and slightly increased the maximum life span (+3.5%). In females, the mean life span and median in metformin-treated groups were slightly decreased (-9.1% and -13.8% respectively, P > 0.05) in comparison to controls, whereas mean life span of last 10% survivors and maximum life span were the same as in controls. Almost half (45%) of control male mice and 71.8% male mice neonatally exposed to metformin survived up to 800 d of age, the same age was achieved by 54.3% of mice in control female group and 30% of metformin-treated females (P < 0.03). Thus, neonatal metformin exposure slows down aging and prolongs lifespan in male but not in female mice.

Indexed as

AgingAnimalsAnimals, NewbornBody TemperatureBody WeightCell Transformation, NeoplasticEstrous CycleFemaleHypoglycemic AgentsInsulin-Like Growth Factor ILongevityMaleMetforminMiceMice, 129 StrainPregnancyHypoglycemic AgentsInsulin-Like Growth Factor IMetforminTOR Serine-Threonine Kinasesbiomarkers of agingcarcinogenesisgenderlife extensionmetforminmiceneonatal

Identifiers

PMID25483062
PMCPMC4353070
OpenAlexW2016629288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.